FLAT Study: First Line Ablation Therapy for Treatment of Paroxysmal Atrial Fibrillation (RAAFT)

Inclusion Criteria: * Informed consent obtained * Two or more documented symptomatic paroxysmal atrial fibrillation episodes during the last 6 months. Episodes should last longer than 30 seconds. * Patients should not be on anti-arrhythmic medication therapy (Class I, III or IV) for AF (other than for cardioversion) or are currently on antiarrhythmic drug (AAD) therapy for any other arrhythmia Exclusion Criteria: * Patients who had a previous ablation for atrial fibrillation * Patients who had presence of severe valvular disease, myocardial infarction and/ or cardiomyopathy * Patients with a left atrial size more than 50 mm * Patients who had more than 2 cardioversions * Patients who have a history of AF for less than 3 months or more than one year * Patients with solely asymptomatic AF * Patients who have AF episodes triggered by another uniform arrhythmia * Patients who actively abuse alcohol or other drugs, which may be causative of AF * Patients with a tumor, or another abnormality which precludes catheter introduction * Patients with a revascularization or other cardiac surgery within 6 months before study treatment * Patients in whom appropriate vascular access is precluded * Patients with a contraindication to treatment with warfarin or other bleeding diathesis participants in another investigational clinical or device trial * Patients who are inaccessible for follow-up psychological problem that might limit compliance * Patients who cannot or will not fulfill the follow-up or protocol requirements * Pregnant women * Patients with severe chronic obstructive pulmonary disease * Patients with Wolff-Parkinson-White (WPW) syndrome * Patients with renal failure requiring dialysis * Patients with hepatic failure